Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | NAAA | Q02083 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL163435 | 0.90 | L3MBTL1 (0.71) | SMN1; SMN2NAAAL3MBTL1GAAMAPT | |
| SCHEMBL16117373 | 0.90 | SMN1; SMN2 (1.00) | SMN1; SMN2NAAAL3MBTL1GAATSHR | |
| SCHEMBL161905 | 0.84 | SMN1; SMN2 (0.81) | SMN1; SMN2NAAAL3MBTL1GAATSHR | |
| SCHEMBL842634 | 0.84 | SMN1; SMN2 (0.81) | SMN1; SMN2NAAAL3MBTL1GAATSHR | |
| SCHEMBL31055438 | 0.84 | L3MBTL1 (0.82) | SMN1; SMN2NAAAL3MBTL1GAATSHR | |
| SCHEMBL13693382 | 0.84 | SMN1; SMN2 (0.87) | SMN1; SMN2NAAAL3MBTL1GAATSHR | |
| SCHEMBL131829 | 0.83 | SMN1; SMN2 (0.87) | SMN1; SMN2NAAAL3MBTL1GAATSHR | |
| SCHEMBL6535127 | 0.83 | SMN1; SMN2 (0.87) | SMN1; SMN2NAAAL3MBTL1GAATSHR | |
| SCHEMBL161025 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1GAAALDH1A1POLB | |
| SCHEMBL6258472 | 0.83 | SMN1; SMN2 (0.79) | SMN1; SMN2NAAAL3MBTL1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856210-B2 | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis | KYOTO UNIVERSITY (JP) | 2018-01-02 | — | — | US | disclosed |
| EP-2611437-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV KYOTO (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2013-08-29 | — | — | US | disclosed |
| EP-2611437-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029994-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225642-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | SMN1; SMN2, SOD1, SOD3 | SMN1; SMN2 1/4885NAAA 2182/4885L3MBTL1 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.